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disability, and results in signiﬁcant personal hardship. Most
available treatments, when tested in high-quality randomised,
controlled trials [32_TD$DIFF], achieve only modest improvements in pain, at
best. Recently, treatments that target central nervous system
function have been developed and tested in small studies.
Combining treatments that target central nervous system function
with traditional treatments directed towards functioning of the
back is a promising approach that has yet to be tested in adequately
powered, prospectively registered[33_TD$DIFF], clinical trials. The RESOLVE trial
will be the ﬁrst high-quality assessment of two treatment programs
that combine central nervous system-directed and traditional
interventions in order to improve chronic low back pain. Aim: To
compare the effectiveness of two treatment programs that combine
central nervous system-directed and traditional interventions at
reducing pain intensity at 18 weeks post randomisation in a
randomised clinical trial of people with chronic low back pain.
Design: Two-group, [34_TD$DIFF]randomised, [35_TD$DIFF]clinical [36_TD$DIFF]trial [37_TD$DIFF]with [38_TD$DIFF]blinding [39_TD$DIFF]of
[40_TD$DIFF]participants and assessors. Participants and [41_TD$DIFF]setting: Two hundred
and seventy[42_TD$DIFF]-ﬁve participants with chronic low back pain that has
persisted longer than 3months and no speciﬁc spinal pathologywill
be recruited from the community and primary care in Sydney,
Australia. Interventions: Both of the interventions contain treat-
ments that target central nervous system function combined with
treatments directed towards functioning of the back. Adherence to
the intervention will be monitored using an individual treatment
diary and adverse events recorded through passive capture.
Participants are informed prior to providing informed consent that
some of the treatments are not active. Blinding ismaintained by not
disclosing any further information. Complete disclosure of the
contents of the intervention has been made with the UNSW HREC
(HC15357) and an embargoed project registration has been made
on the Open Science Framework tomeet the Declaration of Helsinki
requirement for transparent reporting of trial methods a priori[2_TD$DIFF].
Intervention A: Participants randomised to Intervention A will
receive a 12-session treatment program delivered as 60-minute
sessions, scheduled approximately weekly, over a period of 12 to
18 weeks. All treatment sessions are one-on-one. The program
includes a home treatment component of 30 minutes, ﬁve times per
week. The intervention comprises discussion of the participant’s
low back pain experience, graded sensory training, graded motorhttp://dx.doi.org/10.1016/j.jphys.2016.11.001
1836-9553/ 2016 Australian Physiotherapy Association. Published by Elsevier B
creativecommons.org/licenses/by-nc-nd/4.0/).imagery training and graded, precision-focused and feedback-
enriched, functional movement training. Treatment progression is
determined by participant proﬁciency, with mandatory advance-
ment at set time points with respect to a standard protocol.
Intervention B: Participants randomised to Intervention B will
receive a 12-session treatment program of the same duration and
structure as Intervention A. The intervention comprises discussion
of the participant’s low back pain experience, transcranial direct
current stimulation to the motor and pre-frontal cortices, cranial
electrical stimulation, and low-intensity laser therapy and pulsed
electromagnetic energy to the area of greatest pain. Treatment is
delivered according to published recommendations and progressed
with respect to a standard protocol. Measurements: The primary
outcome is pain intensity at 18 weeks post randomisation.
Secondary outcomes will include disability, depression, pain
catastrophising, kinesiophobia,[43_TD$DIFF] beliefs about back pain[3_TD$DIFF], pain self-
efﬁcacy, quality of life, healthcare resource use, and treatment
credibility. Assessment will occur at baseline and at 18, 26 and
52 weeks [44_TD$DIFF]after randomisation. Treatment credibility will be
assessed at baseline and 2 weeks [44_TD$DIFF]after randomisation only.
Analysis: A statistician blinded to group status will analyse the
data by intention-to-treat using linear mixed models with random
intercepts. Linear contrasts will be constructed to compare the
adjusted mean change (continuous variables) in outcome from
baseline to each time point between intervention A and interven-
tion B. This will provide effect estimates and 95% conﬁdence
intervals for any difference between the interventions. Signiﬁ-
cance: Preliminary data suggest that combining treatments that
target central nervous system function with traditional interven-
tions is a promising approach to chronic low back pain treatment. In
the context of modest effects on pain intensity frommost available
treatments, this approach may lead to improved clinical outcomes
for people with chronic low back pain. The trial will determine
which, if either, of two treatment programs that combine central
nervous system-directed and traditional interventions is more
effective at reducing pain intensity in a chronic low back pain
cohort. Central nervous system-directed interventions constitute a
completely new treatment paradigm for chronic low back pain
management. The results have the potential to be far reaching and
change current physiotherapy management of chronic low back
pain in Australia and internationally..V. This is an open access article under the CC BY-NC-ND license (http://
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